Clinical Trial: NCT03819465
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-05-12 |
Study Overview
Brief Summary
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
Official Title
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)
Conditions
Metastatic Non-Small Cell Lung Cancer (NSCLC)
Intervention / Treatment
- Drug: Durvalumab
- Drug: Danvatirsen
- Drug: Oleclumab
- Drug: MEDI5752
- Drug: Pemetrexed
- Drug: Carboplatin
- Drug: Gemcitabine
- Drug: Cisplatin
- Drug: Nab-paclitaxel
- Drug: AZD2936
Other Study ID Numbers
- D933IC00001
- 2018-001748-74
- 2018
Start Date (Actual)
2018-12-27
Primary Completion Date (Actual)
2023-05-23
Study Completion Date (Estimated)
2026-07-01
Enrollment (Actual)
175
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-05-12 |
Study Overview
Brief Summary
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
Official Title
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)
Conditions
Metastatic Non-Small Cell Lung Cancer (NSCLC)
Intervention / Treatment
- Drug: Durvalumab
- Drug: Danvatirsen
- Drug: Oleclumab
- Drug: MEDI5752
- Drug: Pemetrexed
- Drug: Carboplatin
- Drug: Gemcitabine
- Drug: Cisplatin
- Drug: Nab-paclitaxel
- Drug: AZD2936
Other Study ID Numbers
- D933IC00001
- 2018-001748-74
- 2018
Start Date (Actual)
2018-12-27
Primary Completion Date (Actual)
2023-05-23
Study Completion Date (Estimated)
2026-07-01
Enrollment (Actual)
175
Study Type
Interventional
Phase
Phase 1